...
首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Should kidney tubular markers be adjusted for urine creatinine? The example of urinary cystatin C.
【24h】

Should kidney tubular markers be adjusted for urine creatinine? The example of urinary cystatin C.

机译:是否应调整肾小管标记物的尿肌酐水平?尿半胱氨酸蛋白酶抑制剂C的示例。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Evaluation of specific urinary markers with respect to urine creatinine (uCreat) is common. However, as uCreat is a function of both glomerular filtration and tubular secretion, using uCreat for specific tubular markers, suggests that glomerular function is normal, and there is no tubular secretion. Thus, adjusting values of any tubular marker to uCreat, especially in patients with acute or even moderate chronic renal failure, can be misleading. METHODS: Using urine cystatin-C (uCST3) as a model tubular marker for following 120 kidney graft recipients daily, we evaluated the utility of either uCST3 alone or the uCST3/uCreat ratio to detect tubular damage. All positive kidney biopsies were always associated with a uCST3>0.18 mg/L. RESULTS: Using the uCST3/uCreat ratio, discrepancies regarding biopsy status were observed in nine patients (4 false positive, 5 false negative results). In two patients, variability of uCreat appeared to be the most important factor causing inconsistent uCST3/uCreat ratios. With a negative predictive value (NPV) of 85.7%, uCST3/uCreat can lead to errors in clinical interpretation. These errors can be avoided when estimates of tubular damage are based on uCST3 concentrations alone (NPV=100%). CONCLUSIONS: We recommend using the uCST3 value to evaluate the extent of renal tubular damage. Indeed, our conflicting results on uCST3/uCreat can be extended to every marker of tubular function. Evaluating a urine marker specific for renal tubular damage to a second urine marker that is itself strongly dependent upon glomerular or other renal or non-renal conditions, impairs its clinical relevance and may lead to incorrect interpretations. Correction with uCreat can be performed only in pure glomerulopathy, when specific markers of glomerular function are measured (i.e., urinary albumin). In all other cases of renal diseases, such correction is inappropriate and should be avoided. Clin Chem Lab Med 2009;47:1553-6.
机译:背景:关于尿肌酐(uCreat)的特定尿标记物的评估是很普遍的。但是,由于uCreat是肾小球滤过和肾小管分泌的功能,因此使用uCreat作为特定的肾小管标志物,表明肾小球功能正常,没有肾小管分泌。因此,将任何肾小管标记物的值调节至uCreat可能会产生误导,尤其是在患有急性甚至中度慢性肾衰竭的患者中。方法:使用尿半胱氨酸蛋白酶抑制剂C(uCST3)作为模型肾小管标记物,每天跟踪120位肾移植受者,我们评估了单独使用uCST3或使用uCST3 / uCreat比检测肾小管损伤的效用。所有阳性肾活检始终与uCST3> 0.18 mg / L有关。结果:使用uCST3 / uCreat比率,在9名患者中观察到有关活检状态的差异(4例假阳性,5例假阴性)。在两名患者中,uCreat的变异性似乎是导致uCST3 / uCreat比率不一致的最重要因素。 uCST3 / uCreat的负预测值(NPV)为85.7%,可能导致临床解释错误。当仅基于uCST3浓度(NPV = 100%)估算肾小管损伤时,可以避免这些错误。结论:我们建议使用uCST3值来评估肾小管损伤的程度。确实,我们在uCST3 / uCreat上的矛盾结果可以扩展到所有肾小管功能标记。评估对第二肾标志物的肾小管特异性损伤的尿标志物,其本身强烈依赖于肾小球或其他肾或非肾脏疾病,损害其临床相关性并可能导致错误的解释。仅当测量了肾小球功能的特定标志物(即尿白蛋白)时,才能使用uCreat进行校正。在所有其他肾脏疾病病例中,这种校正是不合适的,应避免。临床化学实验室杂志2009; 47:1553-6。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号